women. At 2.5 years cumulative recurrence was 2.5% (95% CI 1.5-3.5) in the screen detected group and 9.7% (7.2-12.2) in the symptomatic group. At 5 years the corresponding rates were 7.8% (6.0-9.6) versus 19.1% (15.6-22.6). Time dependent multivariate analysis showed that the difference in the risk of recurrence between the modes of presentation was significantly different within 2.5 years from diagnosis compared with later than 2.5 years (p = 0.019). The hazard ratio for recurrence within 2.5 years was 0.59 (95% CI 0.34-1.00, p = 0.05) and after 2.5 years was 1.23 (0.84-1.80, p = 0.285).
women. At 2.5 years cumulative recurrence was 2.5% (95% CI 1.5-3.5) in the screen detected group and 9.7% (7.2-12.2) in the symptomatic group. At 5 years the corresponding rates were 7.8% (6.0-9.6) versus 19.1% (15.6-22.6). Time dependent multivariate analysis showed that the difference in the risk of recurrence between the modes of presentation was significantly different within 2.5 years from diagnosis compared with later than 2.5 years (p = 0.019). The hazard ratio for recurrence within 2.5 years was 0.59 (95% CI 0.34-1.00, p = 0.05) and after 2.5 years suggest there may be a role for this technology and we have studied its performance in 100 women prior to breast needle core biopsy (CB) with ethical approval.
Methods: All patients were imaged using a digital infrared breast (DIB) scan (Sentinel BreastScane) prior to breast biopsy.
Analysis of the infrared scans was performed, blinded to biopsy results, in four different ways: Sentinel screening report, Sentinel artificial intelligence (neural network), expert manual review and NoTouch BreastScan a novel artificial intelligence programme.
Results: Of 106 biopsies performed in 100 women 65 were malignant and 41 were benign. Sensitivity of Sentinel screening (53%) and Sentinel neural network (48%) was low but analysis with NoTouch software (70%) was much closer to expert manual review (78%). Sensitivity (78%) and specificity (75%) using NoTouch BreastScan were higher in women under 50 and the combination of mammography and DIB, with NoTouch interpretation, in this age group resulted in a sensitivity of 89%.
Conclusion: DIB using NoTouch BreastScan is an effective adjunctive test for breast cancer detection in women under 70 and appears to be particularly effective in women under 50 where maximal sensitivity (78%) and specificity (75%) were observed.
The combined sensitivity of NoTouch BreastScan and mammography in women under 50 was encouraging at 89%, suggesting a 
